Phase 2 study

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Shanghai Allink Biotherapeutics Co., Ltd.
Registry number NCT06656390
Started 24 October 2024 Today 16 October 2026 Estimated completion 22 October 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Cancer Care Wollongong Wollongong NSW Recruiting
Sunshine Coast University Private Hospital Birtinya QLD Recruiting
Mater Cancer Care Center South Brisbane QLD Recruiting
Macquarie University Hospital Macquarie Australia Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 202

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Men and women ≥18 and ≤75 years old on the day of signing the ICF

* At least 1 measurable lesion per RECIST v1.1

* Expected survival ≥3 months

* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1

* Adequate organ function

* Female participants of childbearing potential or male participants whose partner is a female of childbearing potential agree to use medically effective contraceptive methods from the date of signing the ICF until at least 6 months after the last dose of the IP, and during this period, male participants are not allowed to donate sperms

Exclusion Criteria:

* Active or pre-existing autoimmune diseases that may relapse

* Pleural effusion, pericardial effusion, or intraperitoneal effusion accompanied with clinical symptoms, clinically poorly controlled, or requiring repeated drainage

* Allergies to any component of ALK201 or other monoclonal antibodies

* Primary central nervous system malignancies, or active metastases to central nervous system and/or metastases to meninges

* Combined with ≥ Grade 2 stomatitis and/or nose bleeding at screening

* Vaccinated with live vaccines within 4 weeks prior to the first dose

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Dates on the record

Started 24 October 2024
Estimated completion 22 October 2027
Registry last updated 22 May 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 22 May 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.